دورية أكاديمية
External quality assessment of SARS-CoV-2 serology in European expert laboratories, April 2021.
| العنوان: | External quality assessment of SARS-CoV-2 serology in European expert laboratories, April 2021. |
|---|---|
| المؤلفون: | Mögling R; Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands., Colavita F; National Institute for Infectious Diseases 'Lazzaro Spallanzani' IRCCS (INMI), Rome, Italy., Reimerink J; Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands., Melidou A; European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden., Leitmeyer K; European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden., Keramarou M; European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden., Lapa D; National Institute for Infectious Diseases 'Lazzaro Spallanzani' IRCCS (INMI), Rome, Italy., Francalancia M; National Institute for Infectious Diseases 'Lazzaro Spallanzani' IRCCS (INMI), Rome, Italy., Murk JL; Microvida, location St Elisabeth-Tweesteden Hospital, Tilburg, The Netherlands., Vossen A; Leiden University Medical Center, Leiden, The Netherlands., Carletti F; National Institute for Infectious Diseases 'Lazzaro Spallanzani' IRCCS (INMI), Rome, Italy., Hogema B; Sanquin Research, Amsterdam, The Netherlands., Meijer A; Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands., Deprez L; European Commission, Joint Research Centre (JRC), Geel, Belgium., di Caro A; Unicamillus, International Medical University, Rome, Italy.; IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Italy., Castilletti C; National Institute for Infectious Diseases 'Lazzaro Spallanzani' IRCCS (INMI), Rome, Italy.; IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Italy., Reusken CB; Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands. |
| المصدر: | Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin [Euro Surveill] 2022 Oct; Vol. 27 (42). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: European Centre for Disease Prevention and Control (ECDC) Country of Publication: Sweden NLM ID: 100887452 Publication Model: Print Cited Medium: Internet ISSN: 1560-7917 (Electronic) Linking ISSN: 1025496X NLM ISO Abbreviation: Euro Surveill Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Stockholm, Sweden : European Centre for Disease Prevention and Control (ECDC) Original Publication: Saint-Maurice : Hôpital national de Saint-Maurice |
| مواضيع طبية MeSH: | SARS-CoV-2* , COVID-19*, Humans ; Laboratories ; Antibodies, Viral ; Sensitivity and Specificity ; Immunoglobulin M ; Antibodies, Neutralizing |
| مستخلص: | BackgroundCountries worldwide are focusing to mitigate the ongoing SARS-CoV-2 pandemic by employing public health measures. Laboratories have a key role in the control of SARS-CoV-2 transmission. Serology for SARS-CoV-2 is of critical importance to support diagnosis, define the epidemiological framework and evaluate immune responses to natural infection and vaccine administration.AimThe aim of this study was the assessment of the actual capability among laboratories involved in sero-epidemiological studies on COVID-19 in EU/EEA and EU enlargement countries to detect SARS-CoV-2 antibodies through an external quality assessment (EQA) based on proficiency testing.MethodsThe EQA panels were composed of eight different, pooled human serum samples (all collected in 2020 before the vaccine roll-out), addressing sensitivity and specificity of detection. The panels and two EU human SARS-CoV-2 serological standards were sent to 56 laboratories in 30 countries.ResultsThe overall performance of laboratories within this EQA indicated a robust ability to establish past SARS-CoV-2 infections via detection of anti-SARS-CoV-2 antibodies, with 53 of 55 laboratories using at least one test that characterised all EQA samples correctly. IgM-specific test methods provided most incorrect sample characterisations (24/208), while test methods detecting total immunoglobulin (0/119) and neutralising antibodies (2/230) performed the best. The semiquantitative assays used by the EQA participants also showed a robust performance in relation to the standards.ConclusionOur EQA showed a high capability across European reference laboratories for reliable diagnostics for SARS-CoV-2 antibody responses. Serological tests that provide robust and reliable detection of anti-SARS-CoV-2 antibodies are available. |
| التعليقات: | Erratum in: Euro Surveill. 2022 Oct;27(43):. (PMID: 36305338) |
| References: | Emerg Infect Dis. 2020 Oct;26(10):2353-2360. (PMID: 32723432) Euro Surveill. 2021 Jul;26(27):. (PMID: 34240697) Clin Chem Lab Med. 2021 Aug 05;59(11):1878-1884. (PMID: 34348424) Lancet Glob Health. 2020 Apr;8(4):e488-e496. (PMID: 32119825) Emerg Microbes Infect. 2020 Dec;9(1):1965-1973. (PMID: 32819220) J Clin Microbiol. 2021 Aug 18;59(9):e0055921. (PMID: 34190575) Euro Surveill. 2018 May;23(19):. (PMID: 29766839) Clin Chem Lab Med. 2020 Aug 27;58(12):2121-2130. (PMID: 32853163) Lancet. 2021 Apr 10;397(10282):1347-1348. (PMID: 33770519) Euro Surveill. 2021 Nov;26(45):. (PMID: 34763752) Emerg Infect Dis. 2022 Mar;28(3):672-683. (PMID: 35202525) Open Forum Infect Dis. 2020 Sep 02;7(10):ofaa403. (PMID: 33527081) Emerg Infect Dis. 2018 May;24(5):. (PMID: 29470164) Nat Commun. 2020 Nov 27;11(1):6044. (PMID: 33247152) Nat Med. 2020 Jun;26(6):845-848. (PMID: 32350462) J Clin Microbiol. 2021 Aug 18;59(9):e0076721. (PMID: 34191578) Euro Surveill. 2020 Jul;25(27):. (PMID: 32672149) J Virol Methods. 2021 May;291:114102. (PMID: 33607117) |
| فهرسة مساهمة: | Keywords: COVID-19; EQA; Europe; SARS-CoV-2; antibodies; serology |
| المشرفين على المادة: | 0 (Antibodies, Viral) 0 (Immunoglobulin M) 0 (Antibodies, Neutralizing) |
| تواريخ الأحداث: | Date Created: 20221021 Date Completed: 20221024 Latest Revision: 20221101 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC9585882 |
| DOI: | 10.2807/1560-7917.ES.2022.27.42.2101057 |
| PMID: | 36268736 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1560-7917 |
|---|---|
| DOI: | 10.2807/1560-7917.ES.2022.27.42.2101057 |